The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial.
Chris Verslype
No relevant relationships to disclose
Pascal Hammel
Consultant or Advisory Role - Celgene; Merck Serono; Pfizer
Manuel Hidalgo
No relevant relationships to disclose
Teresa Macarulla
No relevant relationships to disclose
Rocio Garcia-Carbonero
Consultant or Advisory Role - Merck KGaA (I)
Thierry André
Honoraria - Merck Serono
Marc Van Den Eynde
No relevant relationships to disclose
Berta Laquente Saez
No relevant relationships to disclose
Michele Milella
No relevant relationships to disclose
Eric Raymond
Consultant or Advisory Role - Merck Serono
Thea Faivre
Employment or Leadership Position - Merck Serono
Alvin Milner
Employment or Leadership Position - Merck Serono
Dolores Tarabaric
No relevant relationships to disclose
Giuseppe Locatelli
Employment or Leadership Position - Merck Serono
Oliver von Richter
Employment or Leadership Position - Merck Serono
Bernard Laffranchi
Employment or Leadership Position - Merck Serono
Eric Van Cutsem
Research Funding - Merck Serono